FERTIN PHARMA A/S

A soft chew tablet based on proteins includes a core constituting a coherent uncooked mass including: one or more indigestible water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered proteins in an amount of 10 to 60% by weight of the core, and one or more texturizers in an amount of 0.1 to 25% by weight of the core.

A soft chew tablet includes a core constituting a coherent uncooked mass including: one or more indigestible water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered sugar alcohols in an amount of 10 to 45% by weight of the core, one or more texturizers in an amount of 0.1 to 15% by weight of the core, and one or more active ingredients in an amount of 1 to 60% by weight of the core.

Disclosed is an oral nicotine pouch composition comprising nicotine, water in an amount of at least 5% by weight of the pouch composition, alginate, inorganic divalent cations, and at least one pH regulating agent comprising inorganic phosphate. Also disclosed is an oral nicotine pouch composition comprising inorganic multivalent cations and a pouched product.

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

A dosage form for delivery of cannabinoids includes a formulation including: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 30% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

A capsule for peroral delivery of cannabinoids includes a cannabinoid formulation contained in a hard shell or soft shell of the capsule. The formulates include: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 20% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.

A nicotine pouched product is disclosed, the pouched product comprising a pouch composition and a saliva-permeable pouch enclosing said pouch composition, the pouch composition comprising nicotine and a pouch substrate, the pouch substrate comprising water-insoluble fiber, wherein said pouch composition comprises nicotine in an amount of at least 0.25% by weight of the pouch composition, and wherein the pouched product comprises said pouch composition in an amount of no more than 400 mg.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).

A flowpack for oral delivery of active ingredients comprises a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises granulated sugar alcohol particles.

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.